CLINICAL-SIGNIFICANCE OF GENETIC INFLUENCES ON CARDIOVASCULAR DRUG-METABOLISM

被引：9

作者：

ARCAVI, L

BENOWITZ, NL

机构：

[1] SAN FRANCISCO GEN HOSP, DIV CLIN PHARMACOL & EXPTL THERAPEUT, BLDG 30, SAN FRANCISCO, CA 94110 USA

[2] UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA

[3] KAPLAN HOSP, IL-76100 REHOVOT, ISRAEL

来源：

CARDIOVASCULAR DRUGS AND THERAPY | 1993年 / 7卷 / 03期

关键词：

PHARMACOGENETICS; GENETIC POLYMORPHISM; ACETYLATION POLYMORPHISM; DEBRISOQUINE SPARTEINE POLYMORPHISM; P-450; CARDIOVASCULAR; DRUG METABOLISM;

D O I：

10.1007/BF00880154

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Inherited differences in metabolism may be responsible for individual variability in the efficacy of drugs and the occurrence of adverse drug reactions. Among the cardiovascular drugs reported to exhibit genetic polymorphism are debrisoquine, sparteine, some beta-adrenoceptor antagonists, flecainide, encainide, propafenone, nifedipine, procainamide, and hydralazine. The implications of genetic differences in the metabolism of these drugs for cardiovascular therapeutics is the subject of this review.

引用

页码：311 / 324

页数：14

共 94 条

[1]

ALARCONSEGOVIA D, 1969, MAYO CLIN PROC, V44, P664

[2]

ALVAN G, 1982, LANCET, V1, P333

[3]

BATCHELOR JR, 1980, LANCET, V1, P1107

[4] IS THERE A GENETIC-FACTOR IN FLECAINIDE TOXICITY [J].